Completed NA INTERVENTIONAL 1-arm NCT06117085

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

First Clinical Feasibility Study Using the CellFX® Percutaneous Electrode (PE) System for the Treatment of Symptomatic Benign Thyroid Nodules

Sponsor: Pulse Biosciences, Inc.

Conditions Thyroid Nodule (Benign)

Interventions CellFX® Percutaneous Electrode (PE) System

Updated 4 times since 2023 Last updated: Nov 18, 2024 Started: Apr 13, 2023 Primary completion: Nov 18, 2024 Completion: Nov 18, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Thyroid Nodule (Benign), this trial is completed. The trial is conducted by Pulse Biosciences, Inc. and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Dec 2024 — Present [monthly]

Completed NA

Status: Recruiting → Completed
Sep 2024 — Dec 2024 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Dec 2023 — Jul 2024 [monthly]

Recruiting NA

First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pulse Biosciences, Inc.

Data source: Pulse Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Naples, Italy